YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
ALK Abello Inside Information ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the 2026 full-year financial outlook has been upgraded reflecting a strong growth momentum in tablet sales across regions. Revenue is now expected…
First and only needle-free epinephrine nasal spray receives reimburse with conditions recommendation in Canada for adult and pediatric patients weighing 30 kg or greater TORONTO, Oct. 1, 2026 /CNW/ -- ALK-Abelló Pharmaceuticals Inc. Canada…
ALK Abello Inside Information Agreement provides long-term expanded access to Catalent's fast-dissolving (Zydis®) tablet formulation technology. Supply robustness secured with prioritised manufacturing capacity increase of ~40% to 1.1 bill…
ALK-Abelló (CPSE:ALK B) has reshuffled its top ranks, appointing Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy, effective 1 October 2026, as investors weigh what this leadership shift could mea…
ALK Abello Tina A. Olesen, Executive Vice President for Corporate, Portfolio and Product StrategyTina A. Olesen has been appointed Executive Vice President for Corporate, Portfolio and Product Strategy at ALK, effective 1 October 2026. ALK…
ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company's Executive Vice President and CFO, Claus Steensen Sølje, is scheduled to participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthca…
* ALK-Abelló A/S (AKBLF [https://seekingalpha.com/symbol/AKBLF]): Q2 * Revenue increased by 18% to DKK 1,795 million (1,527) . * Tablet sales grew by 22% to DKK 1,013 million (831). * Operating profit (EBIT [https://seekingalpha.com/symbol…
This article first appeared on GuruFocus. Revenue: Q2 revenue grew 18% in local currencies to close to DKK1.8 billion; half-year revenue increased 18% to DKK3.6 billion. EBIT: Q2 EBIT increased 19%, with EBIT margin unchanged at 25%; half-…
ALK Abello ALK announces the appointment of Jacob Glenting as new Executive Vice President (EVP) and head of Global R&D, effective 1 September 2026. This position has been vacant since February 2026. Jacob Glenting is currently EVP, Corpor…
ALK Abello ALK delivers 18% organic revenue growth with operating profit (EBIT) up 19% in Q2 ALK sustained strong momentum in Q2, with double-digit growth across all regions driven by sales of tablets and anaphylaxis products. Operating pr…
ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the UK's National Institute for Health and Care Excellence (NICE) has recommended the company's tree pollen tablet (ITULAZAX®) and house dust mite tablet (ACARIZAX®)…
ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first six months of 2026 in the morning on Thursday, 20 August 2026. Later on the same day, the company will host a presentation for investors and analyst…
ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced the market launch of neffy® 2 mg in Canada following the approval by Health Canada in April 2026. The launch of this first ever nasal adrenaline spray for emergency treatm…
The food allergy market landscape is advancing through a robust clinical pipeline, with key programs being developed by companies such as DBV Technologies (Viaskin [DBV712] Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abell…
ALK Abello ALK announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EURneffy® 1 mg, the first and only needle-free adrenaline treatment for anaphylaxis for children aged 4 an…
ALK Abello Over half (54%) of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed—and nearly 40% do not carry one regularly (n=1,238 ).1 HCP survey data suggests only around half of p…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Wondering whether ALK-Abelló at DKK266.20 is still reasonably priced, or if the recent optimism has already been baked…
ALK Abello At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present data and k…
ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company’s Executive Vice President and CFO, Claus Steensen Sølje, is scheduled to present at the 2026 Jefferies Global Healthcare Conference in New York City taki…
ALK Abello ALK delivers 18% organic revenue growth with operating profit (EBIT) up 22% in Q1 Q1 saw broad-based growth across key categories and regions with sustained, strong momentum in tablet sales in Europe and North America. Operating…
ALK Abello Inside Information ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the 2026 full-year financial outlook has been upgraded reflecting a strong underlying momentum for tablet sales and reduced risks associated with p…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. ALK-Abelló (CPSE:ALK B) has drawn fresh attention after recent trading data showed a 1.5% daily return and a 7.2% gain…
ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first quarter of 2026 in the morning on Tuesday, 5 May 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:3…
ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by man…
Aravax MELBOURNE, Australia and OXFORD, United Kingdom, April 08, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces two a…
ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): ALK-Abelló A/S held its Annual General Meeting on 16 March 2026. The Annual General Meeting transacted the following business: Approval of the annual report 2025 and discharge of the Boa…
ALK Abello ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis, demonstrating that 88% of participants prefer EURneffy®—the first and only approved…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. ALK-Abelló (CPSE:ALK B) has drawn investor attention after reporting full year 2025 results, issu…
This article first appeared on GuruFocus. Q4 Revenue Growth: Increased by 17%, driven by strong performance across all geographies. Full-Year Revenue Growth: Grew by 15% in local currencies to 6.3 billion Danish krona ($1 billion USD). EBI…
ALK Abello The Annual General Meeting of ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) will take place on Monday, 16 March 2026 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting includ…
ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Henriette Mersebach will step down as Executive Vice President, Research and Development, and as a member of the Board of Management, effective 23 February 2026. It h…
ALK Abello ALK’s (ALKB:DC / Nasdaq Copenhagen: ALK B) full-year results came in at the top end of the latest outlook, supported by solid performance in Q4 and continued commercial momentum. ALK expects sustained high organic revenue growth…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. What ALK-Abelló’s Recent Share Performance Tells You ALK-Abelló (CPSE:ALK B) has been under pressure recently, with the…
ALK Abello ALK (ALKB:DC / OMX: ALK B) will publish its annual report for 2025 in the morning on Friday, 20 February 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s…
ARS Pharmaceuticals, Inc. -Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epinephrine auto-in…
ARS Pharmaceuticals, Inc. EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will dist…